The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
DNA Damage and Cancer Immunotherapy: A STING in the Tale
Open accessAbstract
Cancer immunotherapies enhance anti-tumor immune responses using checkpoint inhibitors, such as PD-1 or PD-L1 inhibitors. Recent studies, however, have extended the scope of immunotherapeutics by unveiling DNA damage-induced innate immunity as a novel target for cancer treatment. Elucidating the interplay among the DNA damage response (DDR), cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway activation, and anti-tumoral immunity is critical for the development of effective cancer immunotherapies. Here, we discuss the current understanding of the mechanisms by which DNA damage activates immune responses that target and eradicate cancer cells. Yet, understanding how cancer cells can escape this immune surveillance and promote tumor progression represents an outstanding challenge. We highlight the most recent clinical advances, in particular how pharmacological fine-tuning of innate/adaptive immunity and its combination with DDR inhibitors, ionizing radiation (IR), and chemotherapy can be exploited to improve cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
A diverse range of gene products are effectors of the type I interferon antiviral response
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,433
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Blackford, A. N., & Jackson, S. P. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.015 · Cited by 1,961
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
Cellular senescence and the senescent secretory phenotype: therapeutic opportunities
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., & Kirkland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64098 · Cited by 1,774
cGAS surveillance of micronuclei links genome instability to innate immunity
Mackenzie, K. J., Carroll, P., Martin, C.-A., Murina, O., Fluteau, A., Simpson, D. J., Olova, N., Sutcliffe, H., Rainger, J. K., Leitch, A., et al. (2017) · Nature · doi:10.1038/nature23449 · Cited by 1,752
Chromosomal instability drives metastasis through a cytosolic DNA response
Bakhoum, S. F., Ngo, B., Laughney, A. M., Cavallo, J.-A., Murphy, C. J., Ly, P., Shah, P., Sriram, R. K., Watkins, T. B. K., Taunk, N. K., et al. (2018) · Nature · doi:10.1038/nature25432 · Cited by 1,593
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508
Cytoplasmic chromatin triggers inflammation in senescence and cancer
Dou, Z., Ghosh, K., Vizioli, M. G., Zhu, J., Sen, P., Wangensteen, K. J., Simithy, J., Lan, Y., Lin, Y., Zhou, Z., et al. (2017) · Nature · doi:10.1038/nature24050 · Cited by 1,335
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
Li, T., & Chen, Z. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180139 · Cited by 1,293
Autophagy induction via STING trafficking is a primordial function of the cGAS pathway
Gui, X., Yang, H., Li, T., Tan, X., Shi, P., Li, M., Du, F., & Chen, Z. J. (2019) · Nature · doi:10.1038/s41586-019-1006-9 · Cited by 1,269
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence
Glück, S., Guey, B., Gulen, M. F., Wolter, K., Kang, T.-W., Schmacke, N. A., Bridgeman, A., Rehwinkel, J., Zender, L., & Ablasser, A. (2017) · Nature Cell Biology · doi:10.1038/ncb3586 · Cited by 1,196
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
cGAS is essential for cellular senescence
Yang, H., Wang, H., Ren, J., Chen, Q., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705499114 · Cited by 1,009
Aicardi–Goutières syndrome and the type I interferonopathies
Crow, Y. J., & Manel, N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3850 · Cited by 925
Design of amidobenzimidazole STING receptor agonists with systemic activity
Ramanjulu, J. M., Pesiridis, G. S., Yang, J., Concha, N., Singhaus, R., Zhang, S.-Y., Tran, J.-L., Moore, P., Lehmann, S., Eberl, H. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0705-y · Cited by 912
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902
Nimonkar, A. V., Genschel, J., Kinoshita, E., Polaczek, P., Campbell, J. L., Wyman, C., Modrich, P., & Kowalczykowski, S. C. (2011) · Genes & Development · doi:10.1101/gad.2003811 · Cited by 763
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
Härtlova, A., Erttmann, S. F., Raffi, F. A., Schmalz, A. M., Resch, U., Anugula, S., Lienenklaus, S., Nilsson, L. M., Kröger, A., Nilsson, J. A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.012 · Cited by 716
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Nuclear cGAS suppresses DNA repair and promotes tumorigenesis
Liu, H., Zhang, H., Wu, X., Ma, D., Wu, J., Wang, L., Jiang, Y., Fei, Y., Zhu, C., Tan, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0629-6 · Cited by 650
Dunphy, G., Flannery, S. M., Almine, J. F., Connolly, D. J., Paulus, C., Jønsson, K. L., Jakobsen, M. R., Nevels, M. M., Bowie, A. G., & Unterholzner, L. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.034 · Cited by 648
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Germano, G., Lamba, S., Rospo, G., Barault, L., Magrì, A., Maione, F., Russo, M., Crisafulli, G., Bartolini, A., Lerda, G., et al. (2017) · Nature · doi:10.1038/nature24673 · Cited by 627
Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 620
Xia, T., Konno, H., Ahn, J., & Barber, G. N. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.029 · Cited by 589
Interferon-inducible effector mechanisms in cell-autonomous immunity
MacMicking, J. D. (2012) · Nature Reviews Immunology · doi:10.1038/nri3210 · Cited by 579
Schumacher, T. N., Scheper, W., & Kvistborg, P. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 574
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572
cGAS is essential for the antitumor effect of immune checkpoint blockade
Wang, H., Hu, S., Chen, X., Shi, H., Chen, C., Sun, L., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621363114 · Cited by 563
Konstantinopoulos, P. A., Waggoner, S., Vidal, G. A., Mita, M., Moroney, J. W., Holloway, R., Van Le, L., Sachdev, J. C., Chapman-Davis, E., Colon-Otero, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1048 · Cited by 563
Signalling strength determines proapoptotic functions of STING
Gulen, M. F., Koch, U., Haag, S. M., Schuler, F., Apetoh, L., Villunger, A., Radtke, F., & Ablasser, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00573-w · Cited by 505
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.047 · Cited by 451
Inflammation-driven carcinogenesis is mediated through STING
Ahn, J., Xia, T., Konno, H., Konno, K., Ruiz, P., & Barber, G. N. (2014) · Nature Communications · doi:10.1038/ncomms6166 · Cited by 447
SAMHD1 acts at stalled replication forks to prevent interferon induction
Coquel, F., Silva, M.-J., Técher, H., Zadorozhny, K., Sharma, S., Nieminuszczy, J., Mettling, C., Dardillac, E., Barthe, A., Schmitz, A.-L., et al. (2018) · Nature · doi:10.1038/s41586-018-0050-1 · Cited by 442
Conlon, J., Burdette, D. L., Sharma, S., Bhat, N., Thompson, M., Jiang, Z., Rathinam, V. A. K., Monks, B., Jin, T., Xiao, T. S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300097 · Cited by 434
The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death
Zierhut, C., Yamaguchi, N., Paredes, M., Luo, J.-D., Carroll, T., & Funabiki, H. (2019) · Cell · doi:10.1016/j.cell.2019.05.035 · Cited by 405
Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis
Xia, T., Konno, H., & Barber, G. N. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1404 · Cited by 383
The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication
Tarsounas, M., & Sung, P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0218-z · Cited by 359
Self-citationPARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123319 · Cited by 332
Tight nuclear tethering of cGAS is essential for preventing autoreactivity
Volkman, H. E., Cambier, S., Gray, E. E., & Stetson, D. B. (2019) · eLife · doi:10.7554/elife.47491 · Cited by 303
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Higuchi, T., Flies, D. B., Marjon, N. A., Mantia-Smaldone, G., Ronner, L., Gimotty, P. A., & Adams, S. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0044 · Cited by 285
Konno, H., Yamauchi, S., Berglund, A., Putney, R. M., Mulé, J. J., & Barber, G. N. (2018) · Oncogene · doi:10.1038/s41388-017-0120-0 · Cited by 274
Jiang, H., Xue, X., Panda, S., Kawale, A., Hooy, R. M., Liang, F., Sohn, J., Sung, P., & Gekara, N. O. (2019) · The EMBO Journal · doi:10.15252/embj.2019102718 · Cited by 266
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Wang, Z., Sun, K., Xiao, Y., Feng, B., Mikule, K., Ma, X., Feng, N., Vellano, C. P., Federico, L., Marszalek, J. R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38534-6 · Cited by 253
Gentili, M., Lahaye, X., Nadalin, F., Nader, G. P. F., Puig Lombardi, E., Herve, S., De Silva, N. S., Rookhuizen, D. C., Zueva, E., Goudot, C., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.105 · Cited by 248
Role for BLM in replication-fork restart and suppression of origin firing after replicative stress
Davies, S. L., North, P. S., & Hickson, I. D. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1267 · Cited by 234
Erdal, E., Haider, S., Rehwinkel, J., Harris, A. L., & McHugh, P. J. (2017) · Genes & Development · doi:10.1101/gad.289769.116 · Cited by 227
The Dissolution of Double Holliday Junctions
Bizard, A. H., & Hickson, I. D. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016477 · Cited by 216
Ho, S. S. W., Zhang, W. Y. L., Tan, N. Y. J., Khatoo, M., Suter, M. A., Tripathi, S., Cheung, F. S. G., Lim, W. K., Tan, P. H., Ngeow, J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.010 · Cited by 207
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
Reisländer, T., Lombardi, E. P., Groelly, F. J., Miar, A., Porru, M., Di Vito, S., Wright, B., Lockstone, H., Biroccio, A., Harris, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11048-5 · Cited by 192
Self-citationHuman DNA-PK activates a STING-independent DNA sensing pathway
Burleigh, K., Maltbaek, J. H., Cambier, S., Green, R., Gale, M., James, R. C., & Stetson, D. B. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba4219 · Cited by 175
RPA and Rad51 constitute a cell intrinsic mechanism to protect the cytosol from self DNA
Wolf, C., Rapp, A., Berndt, N., Staroske, W., Schuster, M., Dobrick-Mattheuer, M., Kretschmer, S., König, N., Kurth, T., Wieczorek, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11752 · Cited by 161
The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination
Zhao, W., Wiese, C., Kwon, Y., Hromas, R., & Sung, P. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111058 · Cited by 160
Huang, J., Wang, L., Cong, Z., Amoozgar, Z., Kiner, E., Xing, D., Oršulić, S., Matulonis, U. A., & Goldberg, M. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.083 · Cited by 153
Interferon regulatory factor-3 is an in vivo target of DNA-PK
Karpova, A. Y., Trost, M., Murray, J. M., Cantley, L. C., & Howley, P. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052713899 · Cited by 151
Heijink, A. M., Talens, F., Jae, L. T., van Gijn, S. E., Fehrmann, R. S. N., Brummelkamp, T. R., & van Vugt, M. A. T. M. (2019) · Nature Communications · doi:10.1038/s41467-018-07927-y · Cited by 140
Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS
Gratia, M., Rodero, M. P., Conrad, C., Samra, E. B., Maurin, M., Rice, G., Duffy, D., Revy, P., Petit, F., Dale, R. C., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181329 · Cited by 116
Induction of neoantigen-reactive T cells from healthy donors
Ali, M., Földvári, Z., Giannakopoulou, E., Böschen, M.-L., Strønen, E., Yang, W., Toebes, M., Schubert, B., Kohlbacher, O., Schumacher, T. N., et al. (2019) · Nature Protocols · doi:10.1038/s41596-019-0170-6 · Cited by 112
Bloom syndrome, genomic instability and cancer: the SOS-like hypothesis
Amor-Guéret, M. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.04.023 · Cited by 109
Rapid and Unidirectional Perforin Pore Delivery at the Cytotoxic Immune Synapse
Lopez, J. A., Jenkins, M. R., Rudd-Schmidt, J. A., Brennan, A. J., Danne, J. C., Mannering, S. I., Trapani, J. A., & Voskoboinik, I. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301205 · Cited by 90
Gentili, M., Lahaye, X., Nadalin, F., Nader, G. P. F., Lombardi, E. P., Hervé, S., Silva, N. S. D., Rookhuizen, D. C., Zueva, E., Goudot, C., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.049 · Cited by 72
Lindahl, T. L., Barnes, D. E., Yang, Y., & Robins, P. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370535 · Cited by 62
Cited by
Huang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
Targeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 836
Self-citationTurning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
STING Agonists as Cancer Therapeutics
Amouzegar, A., Chelvanambi, M., Filderman, J., Storkus, W., & Luke, J. (2021) · Cancers · doi:10.3390/cancers13112695 · Cited by 395
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
Meier, P., Legrand, A. J., Adam, D., & Silke, J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00674-x · Cited by 382
Metadata
- Authors
- Reisländer, T., Groelly, F. J., & Tarsounas, M.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 80
- Issue
- 1
- Pages
- 21-28
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W3049241962
- Cited by
- 314
- References
- 81
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.